MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: PATIENTREPORTED OUTCOMES FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL

被引：0

作者：

Redondo, Andres ^{[1
,2
]}

Follana, Philippe ^{[3
,4
]}

Scambia, Giovanni ^{[5
,6
]}

Asselain, Bernard ^{[7
]}

Marme, Frederik ^{[8
,9
]}

Mirza, Mansoor ^{[10
,11
]}

Laudani, Maria Elena ^{[12
]}

Madry, Radoslaw ^{[13
,14
]}

Glasspool, Rosalind ^{[15
,16
,17
]}

You, Benoit ^{[18
,19
]}

Jesus Rubio-Perez, Maria ^{[20
,21
]}

Zamagni, Claudio ^{[22
,23
]}

El-Balat, Ahmed ^{[24
,25
]}

Hardy-Bessard, Anne Claire ^{[26
,27
]}

Oaknin, Ana ^{[28
,29
]}

Ronzino, Graziana ^{[30
,31
]}

Shaw, Bob ^{[32
]}

Nakamura, Hitomi ^{[33
]}

Berton, Dominique ^{[34
]}

Pujade-Lauraine, Eric ^{[35
]}

机构：

[1] La Paz Univ Hosp, Madrid, Spain

[2] GEICO, Dept Med, Madrid, Spain

[3] Ctr Antoine Lacassagne, Nice, France

[4] GINECO, Dept Med Oncol, Nice, France

[5] Fdn Policlin Univ A Gemelli, IRCCS, UOC Ginecol Oncol, Rome, Italy

[6] MITO, Dipartimento Salute Donna & Bambino & Salute Pubb, Rome, Italy

[7] ARCAGY GINECO, Dept Biostat, Paris, France

[8] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany

[9] AGO, Med Fac Mannheim, Mannheim, Germany

[10] Rigshosp, Copenhagen, Denmark

[11] NSGO, Dept Canc Treatment, Copenhagen, Denmark

[12] Univ Turin, St Anna Hosp, Dept Gynecol & Obstet, Turin, Italy

[13] Poznan Univ Med Sci, Poznan, Poland

[14] PGOG, Dept Gynecol Oncol, Poznan, Poland

[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[16] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland

[17] NCRI, Med Oncol, Glasgow, Lanark, Scotland

[18] HCL Ctr Hosp Lyon Sud, Lyon, France

[19] GINECO, Dept Med Oncol, Lyon, France

[20] Reina Sofia Univ Hosp, Cordoba, Spain

[21] GEICO, Dept Med Oncol, Cordoba, Spain

[22] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[23] MITO, Med Oncol Unit, Bologna, Italy

[24] Klinikum Johann Wolfgang Goethe Univ, Frankfurt, Germany

[25] AGO, Dept Gynecol & Gynecol Oncol, Frankfurt, Germany

[26] Ctr CARIO HPCA, Plerin, France

[27] GINECO, Med Oncol, Plerin, France

[28] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[29] GEICO, Gynaecol Canc Programme, Barcelona, Spain

[30] Vito Fazzi Hosp, Lecce, Italy

[31] MITO, Med Oncol Unit, Lecce, Italy

[32] AstraZeneca, Stat, Cambridge, England

[33] AstraZeneca, Global Med Affairs, Cambridge, England

[34] Inst Cancerol Ouest, Med Oncol, St Herblain, France

[35] ARCAGY GINECO, Dept Med Oncol, Paris, France

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O025/#522

引用

下载

页码：A15 / A15

页数：1

共 50 条

[1] Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial
Pujade-Lauraine, E.
Selle, F.
Scambia, G.
Asselain, B.
Marme, F.
Lindemann, K.
Colombo, N.
Madryl, R.
Glasspool, R.
Vergote, I.
Korach, J.
Lheureux, S.
Dubot, C.
Oaknin, A.
Zamagni, C.
Heitz, F.
Gladieff, L.
Rubio-Perez, M. J.
Scollo, P.
Blakeley, C.
Shaw, B.
Ray-Coquard, I
Redondo, A.
ANNALS OF ONCOLOGY, 2023, 34 (12) : 1152 - 1164
[2] Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
Pujade-Lauraine, E.
Selle, F.
Scambia, G.
Asselain, B.
Marme, F.
Lindemann, K.
Colombo, N.
Madry, R.
Glasspool, R. M.
Dubot, C.
Oaknin, A.
Zamagni, C.
Heitz, F.
Gladieff, L.
Rubio-Perez, M. J.
Scollo, P.
Blakeley, C.
Shaw, B.
Ray-Coquard, I. L.
Redondo, A.
ANNALS OF ONCOLOGY, 2021, 32 : S1308 - S1309
[3] OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer
Pujade-Lauraine, E.
Colombo, N.
Glasspool, R.
Asselain, B.
Huzarski, T.
Korach, J.
Marme, F.
Mirza, M. R.
Redondo, A.
Scambia, G.
Blakeley, C.
Milner, A.
Selle, F.
Vergote, I.
ANNALS OF ONCOLOGY, 2017, 28
[4] OREO PHASE IIIB TRIAL: OLAPARIB MAINTENANCE RETREATMENT IN PLATINUM-SENSITIVE, RELAPSED EPITHELIAL OVARIAN CANCER PATIENTS PREVIOUSLY TREATED WITH A PARP INHIBITOR (PARPI)
Pujade-Lauraine, E.
Colombo, N.
Glasspool, R.
Asselain, B.
Huzarski, T.
Korach, J.
Marme, F.
Mirza, M. R.
Redondo, A.
Scambia, G.
Blakeley, C.
Milner, A.
Selle, F.
Vergote, I.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1634 - 1635
[5] OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis-An exploratory joint analysis of the BRCA and non-BRCA cohorts.
Selle, Frederic
Asselain, Bernard
Montestruc, Francois
Bazan, Fernando
Pardo, Beatriz
Salutari, Vanda
Marme, Frederik
Knudsen, Anja Or
Bologna, Alessandra
Madry, Radoslaw
Glasspool, Rosalind
Henry, Stephanie
Korach, Jacob
Lheureux, Stephanie
Shaw, Bob
Santaballa, Ana
Cioffi, Raffaella
Canzler, Ulrich
Lortholary, Alain
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] EFFICACY OF SUBSEQUENT CHEMOTHERAPY FOLLOWED BY PARP INHIBITOR MAINTENANCE IN PATIENTS WITH ADVANCED OVARIAN CANCER IN THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL
Marth, Christian
Mouret-Reynier, Marie-Ange
Lorusso, Domenica
Cropet, Claire
Harter, Philipp
Guerra, Eva
Matsumoto, Takashi
Vergote, Ignace
Colombo, Nicoletta
Maenpaa, Johanna
Lebreton, Coriolan
De Gregorio, Nikolaus
Mosconi, Anna Maria
Rubio, Maria Jesus
Bourgeois, Hugues
Fasching, Peter A.
Hardy-Bessard, Anne-Claire
Denschlag, Dominik
Pujade-Lauraine, Eric
Ray-Coquard, Isabelle
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A21 - A21
[7] Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
Sabatier, Renaud
Rousseau, Frederique
Joly, Florence
Cropet, Claire
Montegut, Coline
Frindte, Johanna
Cinieri, Saverio
Alia, Eva M. Guerra
Polterauer, Stephan
Yoshida, Hiroyuki
Vergote, Ignace
Colombo, Nicoletta
Hietanen, Sakari
Largillier, Remi
Canzler, Ulrich
Gratet, Alain
Marme, Frederik
Favier, Laure
Pujade-Lauraine, Eric
Ray-Coquard, Isabelle
EUROPEAN JOURNAL OF CANCER, 2023, 181 : 42 - 52
[8] SURVIVAL OF PARP INHIBITOR (PARPI) NAIVE OVARIAN CANCER PATIENTS WITH A BRCA-MUTATION RECEIVING MAINTENANCE OLAPARIB AFTER CHEMOTHERAPY FOR FIRST RECURRENCE. AN EXPLORATORY ANALYSIS OF THE SOLO2/ENGOT-OV21 TRIAL
Ledermann, Jonathan A.
Ray-Coquard, Isabelle
Penson, Richard
Lee, Chee
Oza, Amit
Korach, Jacob
Lainez, Nuria
Scambia, Giovanni
Gebski, Val
Colombo, Nicoletta
Welz, Julia
Fujiwara, Keiichi
Lowe, Elizabeth S.
Pujade-Lauraine, Eric
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A243 - A243
[9] Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
Fujiwara, Keiichi
Fujiwara, Hiroyuki
Yoshida, Hiroyuki
Satoh, Toyomi
Yonemori, Kan
Nagao, Shoji
Matsumoto, Takashi
Kobayashi, Hiroaki
Bourgeois, Hughes
Harter, Philipp
Mosconi, Anna Maria
Palacio Vazquez, Isabel
Reinthaller, Alexander
Fujita, Tomoko
Rowe, Philip
Pujade-Lauraine, Eric
Ray-Coquard, Isabelle
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (05)
[10] ENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.
Mirza, M.
Berek, J. S.
Vergote, I.
Wenham, R. M.
Del Campo, J. M.
Oza, A. M.
Mahner, S.
Monk, B. J.
Fabbro, M.
Ledermann, J. A.
Marth, C.
Bruchim, I.
Katsaros, D.
Lorusso, D.
Malander, S.
Dorum, A.
Agarwal, S.
Martell, R. E.
Matulonis, U.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 33 - 34

← 1 2 3 4 5 →